Our data highlights the need to distinguish pro-tumor inflammation from anti-tumor inflammation and supports the intriguing hypothesis that targeting myeloid-driven BIT-associated inflammation would improve therapeutic outcome without thwarting lymphocyte-driven anti-tumor immune reactions. The gene discussed is SIRPA; the disease is neoplasm.